Search
Vemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigationalVemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF. … After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: ZELBORAF ® TABLETAS LACADAS DE 240 MGMirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigationalMirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. … It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significant antimuscarinic activity,[A232553] which is responsible
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: MYRBETRIC® 50 MG TABLETAS DE LIBERACION PROLONGADA, MYRBETRIC® 25 MG TABLETAS DE LIBERACION PROLONGADATofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalKnown adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. … Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: XELJANZ®5MG, เซลแจนซ์ (ยาเม็ด 5 มก.)Ponatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic IndexProducts: ICLUSIG® 15 MG TABLETAS RECUBIERTASCanagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalCanagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise … 2 diabetes mellitus [L5897], [FDA label].
Mixtures: VOKANAMET ® TM_TABLETAS RECUBIERTAS 150/1000 MGCategories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsIodamide
go.drugbank.com/drugs/DB08948ApprovedWithdrawnIodamide is a contrast medium molecule that is no longer marketed in the United States.
Categories: X-Ray Contrast Media, Iodinated, Compounds used in a research, industrial, or household settingIndoramin
go.drugbank.com/drugs/DB08950ApprovedWithdrawnIt is a selective alpha-1 adrenergic antagonist with no reflex tachycardia and direct myocardial depression action. … Indoramin is a discontinued piperidine antiadrenergic drug with the trade names Baratol and Doralese.
Categories: Peripheral alpha-1 blockers, Heterocyclic Compounds, 1-RingHydroxydione
go.drugbank.com/drugs/DB08956ApprovedWithdrawnHydroxydione (Viadril) is a neuroactive steroid used as a general anesthetic.
Hexamethonium
go.drugbank.com/drugs/DB08960Experimentalused a research tool. … A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier.
Synonyms: N,N,N,N',N',N'-hexamethylhexane-1,6-diaminiumDimetotiazine
go.drugbank.com/drugs/DB08967ApprovedDimetotiazine has considerable antiemetic & serotonin antagonistic action used mainly in allergic skin conditions.
Categories: Heterocyclic Compounds, 3-Ring